A new federal effort is underway to keep biopharmaceutical manufacturing stateside — and scale up the production of complex biological drugs.
A new high-tech trade group, dubbed NIIMBL — the pithy shorthand for the National Institute for Innovation in Manufacturing Biopharmaceuticals — on Friday received $70 million from the Department of Commerce. On top of that, NIIMBL will be getting another $129 million from a public-private consortium of 150 companies, academic institutions, and nonprofits, as well as 25 states.
The consortium includes some heavy hitters in the biopharma world, such as Eli Lilly and Biogen. Participating universities include the Massachusetts Institute of Technology, Tulane, Johns Hopkins, the University of Colorado, and many others.
About the Author Reprints
